shim
Abbott A Annual Report 2006 signature
Page 14 of 40
shim
Humira

Humira

Our 2001 acquisition of Knoll Pharmaceuticals positioned Abbott as a leader in biotechnology with Humira, a biologic for treating several debilitating autoimmune diseases. Our clinical development expertise and superior commercial execution have made Humira one of the fastest-growing biologics on the market today.

Anatomy of a growth strategy

Humira represents a pipeline within a product, with the potential to treat multiple autoimmune diseases. It is currently marketed for rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis (AS) and Crohn’s disease. Since its launch in 2003, Humira has grown to more than $2 billion in annual sales — Abbott’s largest brand ever. With three more indications in development, it will remain an important therapy for years to come.

Building a growth driver:

2001
Acquired Knoll Pharmaceuticals, adding biologics expertise and Humira.

2002
Broke ground on a new state-of-the-art biologics manufacturing facility.

2003
Launched Humira for RA and continued clinical studies for additional indications.

2005
Launched Humira for psoriatic arthritis. Exceeded $1 billion in annual sales for the first time.

2006
Submitted Humira for the Crohn’s disease indication and launched it for AS. Exceeded $2 billion in annual sales.

2007
Launched Humira for Crohn’s disease in the United States.

 

 

Humira thumbnails

Humira blocks a protein called tumor necrosis factor (TNF), which plays a key role in causing inflammation. Excess TNF is associated with the progression of autoimmune diseases, such as RA.

Marketed indications:

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Crohn’s disease

Additional indications in development:

  • Psoriasis
  • Juvenile rheumatoid arthritis
  • Ulcerative colitis
 
shim